This will compare Dato-Dxd against docetaxel in previously treated advanced or metastatic non squamous NSCLC.

the first visit will be to sign a consent form to test for a specific biomarker in your archived tumor. If you have that biomarker you will then sign a consent form to participate in the study, if you wish. You will need to come to the clinic for bloodwork and scans to make sure it is safe for you to participate. If it is determined that it is safe for you to continue, you will come to the clinic every month for treatment of your cancer. These visit may also include seeing the doctor, having blood work and completing questionnaires.

$1200.00 You will only be compensated for completed visits.

The main purpose of this clinical trial is to determine whether early non-invasive ventilation (NIV) in individuals diagnosed with amyotrophic lateral sclerosis (ALS) is feasible and is associated with improved quality of life, symptoms, and carbon dioxide levels compared to usual care. Study subjects assigned to the “early NIV” group will start NIV earlier than subjects in the usual care group. The study population will included a total of 48 adults diagnosed with ALS at three Neurology ALS clinics in the United States. Subjects will participate in a total of 5 study visits over a 12-month period.

Once eligible, enrolled subjects are assigned to a group (early NIV or usual care), they will attend a total of 5 in person study visits at the ALS clinic over a 12-month period. At Visit 1, subjects will complete questionnaires and assessments and receive the initial study intervention. Follow-up visits at the ALS clinic will take place every 3 months (Visit 2/Month 3; Visit 3/Month 6; Visit 4/Month 9; Visit 5/Month 12) with the completion of questionnaires and assessments plus review of NIV data as applicable.

The purpose of this clinical research study is to learn more about the use of the investigational drug, deucrictibant, for the prevention and treatment of Acquired Angioedema due to C1 Inhibitor Deficiency (AAE-C1INH) attacks. The study consists of a Screening Phase (up to 10 weeks), followed by a 12-weeks Prophylaxis Treatment Phase (Part 1), an On-demand Treatment Phase (Part 2) and an Open-Label On-demand Treatment Phase (Part 3). These are all described below. If you provide your consent to take part in the study and you are declared eligible to participate, your overall study participation will last approximately 15 months (60 weeks). During this study you will be asked to complete an electronic diary daily. At the study visits you will have blood samples collected. Vital signs, EKGs, and physical exams will be performed.

If you decide to take part in this research study, you will have a screening phase (up to 10 weeks), followed by a 12-week Prophylaxis Treatment Phase (Part 1), an On-demand Treatment Phase (Part 2) and an Open-Label On-demand Treatment Phase (Part 3). If you provide your consent to take part in the study and you are declared eligible to participate, your overall study participation will last approximately 15 months (60 weeks). where you will have procedures to determine if you meet the requirements to be in the study. These include a physical exam and an electrocardiogram (ECG) which will measure the electrical activity of your heart. You will also be required to give blood and urine samples. You will also need to complete a daily electronic diary. If you are a woman who can have children, you will also need to take pregnancy tests.

This study examines how speakers change their language use as they age. Sociolinguistic interviews will be used to document and analyze features of English in Pennsylvania. Sociolinguistic interviews will be conducted between the investigator(s) and the participant(s). Participants will be invited to complete the recorded interviews at different intervals in time. The hypothesis is that language use will change as a speaker ages - as social pressures and lifestyle change, so will language.

In this study, the interviewer will ask you a series of questions about your life. The following are some example topics you may be asked about: Personal background (e.g., place of birth, school, work, family, life in Pennsylvania), Leisure, media, everyday life (e.g., hobbies, dreams, sports and social events) Life experiences (e.g., favorite childhood memories, experience during Covid lockdown) Personal beliefs (e.g., spirituality, superstitions) Language (e.g., thoughts about language use and change) The interview will be audio recorded (no video). You will also be asked to complete a background questionnaire so that we can learn more about your life. When filling out the background questionnaire, you are free to skip any questions you prefer not to answer. At the end of the study, we may ask you if you would be interested in being contacted for follow-up interviews.

$20.00

To determine whether the addition of stereotactic ablative radiotherapy (SABR) to the primary tumor in combination with immunotherapy improves outcomes compared to immunotherapy alone in patients with metastatic, unresected, renal cell carcinoma (RCC).

The patient will either get immune therapy (either 2 immune therapy drugs or immune therapy plus a VEGF targeted therapy), or get immune therapy plus radiation therapy. The radiation treatments will be given on 3 different days over the course of 1-3 weeks. Immune therapy will continue until it is no longer working. After the treatment is stopped, the doctor and study team will monitor the patient every 6 months for 5 years after treatment and then annually for 3 years.

This study will look at the safety and effectiveness of cannabigerol (CBG)/cannabidiol (CBD) in the treatment of chemotherapy induced peripheral neuropathy.

You must attend all scheduled study visits, tell the study doctor about all medications you are taking (including over-the-counter medicines), and let the study team know how you are feeling. Patients must come to clinic visits (about every 4 weeks) for health checks, blood tests and surveys, take the hemp oil (CBG/CBD) twice a day for 12 weeks, complete a drug diary, return unused oil on their next visit, and answer phone calls between visits.

$500.00 if substudy completed

This research aims to investigate how memory functions in cognitively healthy individuals by characterizing age-related differences in memory performance and cognitive processes.

Individuals will be asked to complete computer-based and paper-and-pencil tasks with a researcher. These tasks are designed to assess memory and cognition during a single session. This session can be separated at the request of the participant.

$10/hour

The study will evaluate the effectiveness and safety of ICOTROKINRA compared to placebo in participants with moderate to severe Crohn's disease. The participants will be randomized to one of three treatment groups in a 1:1:1 ration and will receive one of the two drug induction regimens versus placebo. At week I-12 of induction treatment (study 1 or study 2 induction), the participants will be evaluated, and if they achieved clinical response or clinical remission, they could then continue treatment in the Maintenance study for 40-weeks. The response to icotrokinra in the study participants will be evaluated by blood draws to test for biomarkers and PK, study symptoms questionnaires (e.g. stool frequency and pain), and colonoscopy with biopsies. They will also have the physical evaluations, ECG, suicidality assessment, pregnancy testing and monitoring of hypersensitivity reactions, along with test for tuberculosis and other infections. In both induction studies and in the maintenance treatment, participants will receive one of the icotrokinra dose or placebo daily oral pill. After the completion of maintenance treatment, the participants could enter open-label extension study for the 4 years. The screening of potential subject will take six weeks, and at least two in-person visits. Eligible participants who signed informed consent can be enrolled in the induction treatment phase, with visit day 0, week 2, week 4, week 8 and week 12. The safety follow-up visit will be held four weeks after the last dose for eligible participants. Dosing will be done on-site during these visits: day 0, and weeks 2, 4, 8, and 12 if starting the maintenance. Biopsy samples will be collected at the screening and week 12 of induction/start of maintenance. During the maintenance phase of treatment for the responders there will be eleven in-person visits including M-0. Colonoscopy exam will be done at M-12, and M-40 weeks to evaluate a response to the treatment.

Participants will be required to sign the informed consent. There will be at least two screening visits on-site. If eligible, participants will be required to attend five in-person visits, comply to the instructions by the study team, have colonoscopy and blood draws done, take medication daily. They will be asked to complete daily diaries of the disease symptoms. Other tests that will be done to ensure safety are ECG, physical exams, target exams, answer questions on tuberculosis and other infections, provide stool samples and urine pregnancy tests if applicable.

$3,122

The study will evaluate the safety and effectiveness of ICOTROKINRA treatment compared to placebo in participants with moderately to severely active ulcerative colitis. For the induction treatment (12 -weeks), the participants will be randomized to one of the two doses of drug icotrokinra or the placebo (2:1). At week 12 of induction, the participants will be evaluated, and clinical responders will be rerandomized to the drug treatment or placebo. Non-responders will not be randomized but could continue to the maintenance treatment (40-weeks). The study participants will have response to the treatment evaluated by blood draws to test for biomarkers and PK, study symptoms questionnaires (e.g. stool frequency and pain), and colonoscopy with biopsies. They will also have the physical evaluations, ECG, suicidality assessment, pregnancy testing and monitoring of hypersensitivity reactions, along with test for tuberculosis and other infections. The potential participants will enter screening process after they sign the informed consent. The screening for eligibility lasts six weeks and included at least two visits, the clinic visit, and the endoscopy with biopsies. If eligible for the treatment induction, five in-person visits will be held on day 0, week 2, week 4, week 8 and week 12. Except on the visit days, patients will dose at home per the team's instructions. The safety follow-up visit will be held four weeks after the last dose for eligible participants. If eligible to continue treatment after the 40-weeks of maintenance (eleven in-person visit), participants could receive treatment for another four years with in-person visits every eight weeks in the long-term extension. Endoscopy exam will be done at screening, week 12 (end of induction), week 40 (end of maintenance). or disease evaluation (ED)

Participants will be required to sign the informed consent and understand their responsibilities to participate. There will be at least two screening visits on-site. If eligible, participants will be required to attend five in-person visits during the induction treatment, comply to the instructions by the study team, have colonoscopy and blood draws done, take medication daily. They will be asked to complete daily diaries of the disease symptoms. Other tests that will be done to ensure safety are ECG, physical exams, target exams, answer questions on the topic of suicide, about tuberculosis and other infections, provide stool samples and urine pregnancy tests if applicable.

$3000

This study examines how physical health and emotional well-being differ across ages in children, adolescents, and young adults with cancer, cancer survivors, and individuals without a history of cancer. The goal of the study is to better understand how experiences such as fatigue, pain, sleep, physical activity, mood, anxiety, and quality of life vary at different ages and at different points in the cancer journey (during treatment versus after treatment), and how factors like treatment intensity and family resources may influence these experiences. Participants will be asked to complete a set of online questionnaires about their physical health, daily functioning, and emotional well-being. No medical procedures or treatments are involved.

Participants will be asked to complete a set of online questionnaires about their physical health, daily functioning, and emotional well-being. No medical procedures or treatments are involved. The questionnaires will take approximately 45 minutes to complete. - For children aged between 2 and 7 years old, we ask that parents report on behalf of their child. - For children/adolescents aged between 8 and 17 years old, we ask that they complete the survey themselves. Parents may also report on behalf of their child if the child is unwilling or unable to complete the survey themselves. - For young adults aged between 18 and 24 years old, we ask that they complete the survey themselves. Parents may not complete the survey on their behalf.

This research study is being done to see how well the Study Drug, also called donidalorsen (ISIS 721744), works and if it is safe for children with HAE age 2 to less than 12 years old. Donidalorsen is approved in the United States to prevent HAE attacks in adolescent and adult patients 12 years of age or older. The Study Drug is designed to lower the amount of a protein, known as prekallikrein (PKK), which is made by the liver. When PKK is made by the liver and released into the blood stream, it can lead to HAE attacks. Therefore, the purpose of this study is to assess if reducing the amount of PKK can reduce your child’s HAE attacks and to assess the safety of donidalorsen for children with HAE age 2 to less than 12 years old. This study is an open-label study which means that your child and all participants enrolled in the study will receive active Study Drug. Study participants will receive a subcutaneous (under the skin) injection of donidalorsen once every 4 weeks. The Study Drug dose (10, 40 or 80 mg) will be determined by your child’s body weight and may change during the study. Following screening, you and your child will be asked to come to the study site for 14 visits over about 1 year during the initial treatment period. There is also a Post-Treatment Period your child may choose to enter, which requires 2 phone calls and 1 final visit over 13 additional weeks.

This study is an open-label study which means that your child and all participants enrolled in the study will receive active Study Drug. Study participants will receive a subcutaneous (under the skin) injection of donidalorsen once every 4 weeks. The Study Drug dose (10, 40 or 80 mg) will be determined by your child’s body weight and may change during the study. Following screening, you and your child will be asked to come to the study site for 14 visits over about 1 year during the initial treatment period. There is also a Post-Treatment Period your child may choose to enter, which requires 2 phone calls and 1 final visit over 13 additional weeks. During the Study Treatment and Post-Study Treatment Periods, there is also the option to have some of your child’s visits done by a home health care nurse. At each study visit, height and weight will be collected. A physical exam will be performed. An ECG and vital signs will be collected, paper questionnaires will need to be completed, you and/or child will be asked questions about your child's health, medications and medical history. Any HAE attacks will need to be reported to the study staff.

To determine whether induction IO and chemotherapy prior to CCRT+IO improves progression-free survival (PFS) compared to CCRT+IO alone.

The patient will either get induction therapy, chemoradiation with pembrolizumab, and pembrolizumab maintenance therapy for up to 2 years, or chemoradiation and pembrolizumab followed by pembrolizumab maintenance therapy for up to 2 years. Induction therapy means they will receive chemotherapy with cisplatin and paclitaxel once a week for 6 weeks, plus pembrolizumab every 3 weeks for 2 doses, before starting chemoradiation and pembrolizumab. After the patient finishes treatment, they will check the patient every 3 months for the first 2 years after treatment. After that, they will check every 6 months for 3 years. This means the patient will keep seeing their doctor for 5 years after treatment.

The study aims to quantify the effects of blue-enriched white light on cognitive performance.

There will be only one visit where participants will complete cognitive tasks and subjective evaluations of the indoor experimental space.

15

The purpose of this study is to understand if an investigational treatment (pasritamig) added to docetaxel for progressive metastatic hormone resistant prostate cancer will work better than docetaxel alone.

Participants must come to all study visits, take the medication as instructed, tell the study how you are feeling and tell the study team about any medications you are taking, especially over the counter medications.

The goal of this project is to understand how the brain supports semantics and how this changes as we grow older.

There will be one, in-person, 90-minute session that will include computer tasks and an MRI. All activities will be at the University Park Campus.

$40 and free parking

This project seeks to determine how e-cigarette (EC) physical design features, including those that allow the user to manipulate the quality and quantity of aerosols, affect exposure and toxicity from oxidants and other aerosol constituents.

Subjects will attend 8 study visits over the course of 14 weeks to collect various biological samples (such as blood draws, exhaled breath samples, saliva samples). They will be given a study provided e-cigarette that they will use during and between the study visits. There will also be surveys to complete throughout the study.

900

We are testing an experimental drug, ADX-324, as a potential new treatment to help prevent HAE attacks. We are doing this study to find out if an injection of ADX-324 once every 3 months or every 6 months under the skin (subcutaneous) is safe, and if it can reduce the severity and number of HAE attacks.

The total study duration is up to 8 months (up to 2 months for screening before the first dose of ADX-324 or placebo, one dose of ADX-324 or placebo at Day 1 and again 3 months later (Week 13), and follow-up visits for up to 6 months after the first dose). You will need to answer questions about your health/HAE attacks, provide blood samples, undergo routine urine laboratory tests, receive the trial drug, undergo electrocardiogram (ECG), complete questionnaires about the quality of your life, undergo physical exams, and provide HAE attack information.

Endometriosis is a common condition that can sometimes affect the nerves and may also impact heart and blood‑vessel health. In this study, we will use routine medical tests that show how the nervous system and cardiovascular system work together. Women with and without endometriosis will go through standard tilt testing - laying still on a table while the head of the table is tilted upward. Blood pressure and heart rate are measured. Participants then wear a blood pressure monitor for 24 hours.

Participants will go through standard tilt testing (laying down on a table that is tilted head up) and 24-hour blood pressure monitoring (wearing a portable blood pressure monitor while going about their day for one day).

100

Sleep and circadian problems are associated with deleterious social, emotional, and cognitive outcomes, yet are modifiable. This prospective study will adapt, optimize, and test an empirically supported behavioral intervention that addresses common sleep and circadian problems of autistic adults, who are at increased risk for mental health disorders, using a transdiagnostic approach. The knowledge gained from this study will address a critical need for accessible transdiagnostic sleep interventions for autistic adults, who experience a broad range of sleep and circadian problems at high rates and often lack access to specialty care treatment.

You will need to complete self-report assessments at baseline and post-treatment, as well as collect data at home for 2 weeks by wearing a physical activity monitor on your wrist, and completing sleep diaries (short questionnaires) each day. You will also need to complete 6 weekly 50 minute sessions delivered individually by trained clinicians. You will also complete a 30-minute semi-structured interview at post-treatment with the study coordinator.

$75.00

This Study is being done to understand how well INCB123667 works, how safe it is, and how well it is tolerated in people with platinum-resistant ovarian cancer whose tumors have high levels of cyclin E1.

On certain visit days, subject will need to take Study Drug tablets at the Study Site instead of at home. On those days you must fast (no food or drinks) for 8 hours before your visit, so that certain blood tests can be done before you take your Study Drug.

This study is comparing two treatments for the treatment of melanoma.

You will need to come to the clinic twice before start study treatment. The first time is to sign permission to send your tumor to be tested for specific changes. If those changes are in the tumor you will be brought back to the clinic and invited to participate in the study. After testing and scans are done to make sure it is safe for you to take part in the study, you will begin treatment. You will come to the clinic every 3-4 weeks for treatment. You will continue treatment until it no longer works, you no longer wish to receive treatment, or the study doctor feels it is not safe for you to continue.

$60.00 for each completed visit

The purpose of this study is to explore outdoor lighting and its environmental impact, focusing on human perception of these factors. Participants will undergo various tests to evaluate their subjective and objective responses to different light levels and chromaticities.

Participants will complete a demographic survey, will undergo screening tests to assess their visual acuity. If eligible, they will evaluate various lighting environments through a questionnaire and complete an object detection test before and after a brief training session. The total duration of the experiment will be approximately 1 hours.

$20

The purpose of this study is to examine how different acoustic playback methods affect the understanding of speech.

There will be one in person session in the Hammond building on University Park Campus. The session will last approximately 1 - 1.5 hours. During this session you will listen to audio recordings over headphones and loudspeakers and will complete a speech intelligibility task - you will need to listen for a certain talker and indicate what the talker said. You will receive training before completing the task. You will wear a sensor on one of you fingers that measures your physiological response including heart rate, body temperature, and perspiration for the duration of the session. When wearing the headphones, your head motion will be tracked. A hearing screening will be done at the start of your scheduled time to confirm eligibility for the study. If you don't meet the requirements, you will receive $5 in cash. If you do meet the requirements and complete the study, you will receive $25 in cash.

$25

NUZ-001 ((S)-monepantel) is a synthetic drug that aims to stimulate a natural cleaning mechanism called autophagy that removes the build-up of waste products in cells. In patients with ALS, autophagy can be impaired, leading to the toxic build-up of waste products, causing the motor neuron to die.

If you qualify for this regimen, you will be randomly assigned to take either active study drug or placebo. This is a double-blind, placebo-controlled study. This means that participants are selected by chance (like tossing a coin) to be in 1 of 2 groups – this is called “randomization.” “Double-blind” means that neither you, the study doctor, nor any of the study staff will know whether you are receiving active drug or placebo. However, your study doctor can find out in case of an emergency. The placebo looks and feels exactly like the study drug but contains no active drug.

$700

This study examines how participation in sports fandom as a leisure activity shapes social connection and experiences of belonging. Through interviews and optional reflective diaries, the research explores how fans interact with others, build relationships around shared team identities, and understand the role of fandom in their everyday social lives. The goal is to better understand how leisure-based fan communities may help reduce feelings of loneliness and social isolation.

Participants will complete a 60–90 minute interview about their experiences as fans of the Philadelphia Eagles and/or Philadelphia Phillies to explore how fandom relates to their social interactions and leisure activities. Participants may also choose to complete an optional 4–6 week fan experience log, where they briefly note fandom-related activities or interactions (for example watching games with others, attending events, or participating in fan discussions).

The purpose of this voluntary research study is to evaluate the effects of pumitamig compared with placebo in combination with chemotherapy.

Participants must come to all study visits, take the medication as instructed, tell the study how you are feeling and tell the study team about any medications you are taking, especially over the counter medications.

$50.00 per visit

This study is being done to answer the following question: How can a home-based physical activity program best meet the unique language and cultural preferences of Hispanic or Latino/a AYA survivors of cancer? In order to develop a culturally-tailored physical activity program that works well, we know we must address the unique language and cultural needs of Hispanic or Latino/a AYA survivors of childhood cancer. We are doing this study because we want to find out what ideas work best to encourage Hispanic or Latino/a childhood cancer survivors to stay physically active after receiving cancer treatment.

complete participant contact forms, surveys and questionnaires, social media interaction with participant group, wearing an exercise tracker (FitBit).

($30 per each qualitative interview completed

We are doing this study because we want to find out if this study therapy is better or worse than the usual drug therapy for your meningioma. The usual is defined as the standard of care most people get for meningiomas that have come back after treatment.

Your participation in this study will last a maximum of 4 years. If you are randomized to Group 1, your study doctor will discuss the usual drug treatment options with you and you will be followed for up to 24 months. Your total participation could be up to 14 research visits which includes up to 6 months of treatment and 18 months of follow up. If your meningioma progresses within the first 12 months, you may switch to Group 2 and the 24 month follow-up clock restarts. If you are randomized to Group 2, you will receive the study drug once every 4 weeks for up to 4 times (total duration of 3 months). If after 4 doses your meningioma has not grown and you are tolerating the study treatment, you may receive 2 more doses of study drug. Your total participation for Group 2 could be up to 14 research visits which includes up to 6 months of treatment and 18 months of follow up.

The study is researching an experimental drug called mibavademab. The study is focused on patients with a condition called Functional Hypothalamic Amenorrhea (FHA). FHA is a condition where a woman stops menstruating because the brain is not sending the correct hormonal signals to the ovaries, which then are not able to cycle and ovulate properly. The aim of the study is to see how well the study drug helps the body make the hormones necessary for ovulation and reproduction, and to assess its safety.

Subjects will have 18 in person visits, 1 EKG, 8 blood draws, pregnancy tests, 2 Dexa scans, transvaginal ultrasound, menstrual monitoring, optional blood sample for DNA isolation. Participation will last approximately 11 months.

To see how well amivantamab works in immunosuppressed patients with cutaneous squamous cell cancer.

Participants will need to come to the clinic every week for the first four weeks of treatment while you are getting the amivantamab. After that you will come in monthly for treatment. You will continue treatment until it stops working, you no longer want to participate in the trial or the doctor\ thinks it is no safe for you to participate. Make sure to tell the study team how you are feeling and any medications that you er taking.